MAPT and Alzheimer disease: For example, acute pharmacological HDAC6 inhibition with tubastatin A (TBST) alleviated behavioral and cognitive deficits in transgenic tau or Aβ mouse models18,19, spurring significant interest in using HDAC6 inhibitors as AD therapies.